CARsgen Therapeutics Holdings Limited reported unaudited consolidated earnings results for the first half ended June 30, 2021. For the period, the company reported operating loss of RMB 234,259,000 against RMB 145,595,000 a year ago. Loss for the periods and attribute to the equity holders of the company was RMB 4,393,846,000 against RMB 540,842,000 a year ago. Basic and diluted loss per share attributable to owners of the company was RMB 19.68 against RMB 2.73 a year ago.